Pharmacovigilance programme in India (PvPI): History, Current scenario, future aspects and role in COVID 19

According to WHO, Pharmacovigilance (PV) is characterized as the science and exercises identifying with the recognition, appraisal, comprehension and anticipation of unfavourable impacts or some other medication related issue. It is an important part of our medication guideline framework. As we know, India is the world's second most populated country with very nearly one billion dynamic and potential medication buyers and clients. Though our country is participating in Uppsala Monitoring Centre, its obligation to that data base is by and pretty much nothing. This issue is due to the lack of proper ADR (Adverse drug reaction) monitoring system and awareness among associates of medicines and health workers. PV program mainly aims for patient care, patient safety and monitoring of adverse drug reaction. For the accurate practice of PV in India, there are need of more clinical preliminaries and clinical examinations. For the safe and sensible use of medication, a perfectly working PV system is mandatory. PV will be invaluable in India not only for medical services experts, regulatory authorities, pharmaceutical organizations but also for the consumers to screen the medicines. This article gives a methodical audit of the pharmacovigilance program in India (PvPI) from its starting point to the current situation and furthermore examines the future parts of pharmacovigilance program in India.

[1]  Vijender Singh,et al.  Pharmacovigilance: Adverse drug reactions (ADRs) in pediatric patients in Ethiopia. Retrospective study , 2021 .

[2]  Y. Al-Worafi,et al.  Knowledge, attitude and experience of pharmacist in the UAE towards pharmacovigilance , 2021 .

[3]  B. Meher Need of Vibrant Vaccine Pharmacovigilance During Current Global COVID-19 Pandemic: More Than Ever , 2021, Journal of pharmacy & bioallied sciences.

[4]  S. Naik Review on Pharmacovigilance , 2020 .

[5]  V. Hemalatha,et al.  Pharmacovigilance, Adverse Drug Reactions and Future Aspects of Pharmacovigilance in India:A Review Article , 2019 .

[6]  Lovely Joylen Castelino,et al.  A national approach to pharmacovigilance: The case of India as a growing hub of global clinical trials , 2019, Research in social & administrative pharmacy : RSAP.

[7]  Jyoti B. Gadhade,et al.  Pharmacovigilance programme of India: revival of the renaissance , 2018, International Journal of Basic & Clinical Pharmacology.

[8]  V. Kalaiselvan,et al.  Pharmacovigilance in India: Present Scenario and Future Challenges , 2018, Drug Safety.

[9]  J. Glanz,et al.  Addressing Parents' Vaccine Concerns: A Randomized Trial of a Social Media Intervention. , 2018, American journal of preventive medicine.

[10]  M. Crowther,et al.  Anaesthesia for paediatric patients: Minimising the risk , 2018 .

[11]  M. Lahkar,et al.  An update on the Pharmacovigilance Programme of India , 2015, Front. Pharmacol..

[12]  Sachin Manocha,et al.  Comparative study of the efficacy and safety of theophylline and doxofylline in patients with bronchial asthma and chronic obstructive pulmonary disease , 2015, Journal of basic and clinical physiology and pharmacology.

[13]  S. Suke,et al.  Role of Pharmacovigilance in India: An overview , 2015, Online journal of public health informatics.

[14]  Kalaiselvan,et al.  Indian Pharmacopoeia Commission's Partners for Promoting Public Health , 2015 .

[15]  J. Prakash,et al.  Pharmacovigilance programme of India , 2012 .

[16]  A. Kumar Past, present and future of pharmacovigilance in India , 2011 .

[17]  L. de Jong-van den Berg,et al.  Pharmacists' role in reporting adverse drug reactions in an international perspective , 2004, Pharmacoepidemiology and drug safety.

[18]  J. Fudin,et al.  Prescribing privileges among pharmacists in Veterans affairs medical centers. , 2001, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[19]  G. Danan,et al.  Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. , 1993, Journal of clinical epidemiology.